These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 14631376)

  • 21. Outcome evaluation in pre-trastuzumab era between different breast cancer phenotypes: a population-based study on Italian women.
    Cortesi L; De Matteis E; Cirilli C; Marcheselli L; Proietto M; Federico M
    Tumori; 2012 Nov; 98(6):743-50. PubMed ID: 23389361
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Akt is frequently activated in HER2/neu-positive breast cancers and associated with poor prognosis among hormone-treated patients.
    Tokunaga E; Kimura Y; Oki E; Ueda N; Futatsugi M; Mashino K; Yamamoto M; Ikebe M; Kakeji Y; Baba H; Maehara Y
    Int J Cancer; 2006 Jan; 118(2):284-9. PubMed ID: 16049961
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Extreme loss of immunoreactive p-Akt and p-Erk1/2 during routine fixation of primary breast cancer.
    Pinhel IF; Macneill FA; Hills MJ; Salter J; Detre S; A'hern R; Nerurkar A; Osin P; Smith IE; Dowsett M
    Breast Cancer Res; 2010; 12(5):R76. PubMed ID: 20920193
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Biological and prognostic relevance of mitogen-activated protein kinases in pancreatic adenocarcinoma.
    Handra-Luca A; Lesty C; Hammel P; Sauvanet A; Rebours V; Martin A; Fagard R; Fléjou JF; Faivre S; Bédossa P; Ruszniewski P; Couvelard A
    Pancreas; 2012 Apr; 41(3):416-21. PubMed ID: 22158075
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Expression of YES-associated protein (YAP) and its clinical significance in breast cancer tissues.
    Cao L; Sun PL; Yao M; Jia M; Gao H
    Hum Pathol; 2017 Oct; 68():166-174. PubMed ID: 28899737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Dissecting the predictive value of MAPK/AKT/estrogen-receptor phosphorylation axis in primary breast cancer to treatment response for tamoxifen over exemestane: a Translational Report of the Intergroup Exemestane Study (IES)-PathIES.
    Szijgyarto Z; Flach KD; Opdam M; Palmieri C; Linn SC; Wesseling J; Ali S; Bliss JM; Cheang MCU; Zwart W; Coombes RC
    Breast Cancer Res Treat; 2019 May; 175(1):149-163. PubMed ID: 30680659
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Human epidermal growth factor receptor 2 overexpression as a prognostic factor in a large tissue microarray series of node-negative breast cancers.
    Chia S; Norris B; Speers C; Cheang M; Gilks B; Gown AM; Huntsman D; Olivotto IA; Nielsen TO; Gelmon K
    J Clin Oncol; 2008 Dec; 26(35):5697-704. PubMed ID: 19001334
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A Ki67/BCL2 index based on immunohistochemistry is highly prognostic in ER-positive breast cancer.
    Ali HR; Dawson SJ; Blows FM; Provenzano E; Leung S; Nielsen T; Pharoah PD; Caldas C
    J Pathol; 2012 Jan; 226(1):97-107. PubMed ID: 21953021
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Validation of cytoplasmic-to-nuclear ratio of survivin as an indicator of improved prognosis in breast cancer.
    Rexhepaj E; Jirstrom K; O'Connor DP; O'Brien SL; Landberg G; Duffy MJ; Brennan DJ; Gallagher WM
    BMC Cancer; 2010 Nov; 10():639. PubMed ID: 21092276
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Association between androgen receptor expression, Ki-67 and the 21-gene recurrence score in non-metastatic, lymph node-negative, estrogen receptor-positive and HER2-negative breast cancer.
    Vera-Badillo FE; Chang MC; Kuruzar G; Ocana A; Templeton AJ; Seruga B; Goldstein R; Bedard PL; Tannock IF; Amir E
    J Clin Pathol; 2015 Oct; 68(10):839-43. PubMed ID: 26076967
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Prognostic significance of phosphorylated P38 mitogen-activated protein kinase and HER-2 expression in lymph node-positive breast carcinoma.
    Esteva FJ; Sahin AA; Smith TL; Yang Y; Pusztai L; Nahta R; Buchholz TA; Buzdar AU; Hortobagyi GN; Bacus SS
    Cancer; 2004 Feb; 100(3):499-506. PubMed ID: 14745865
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Genomic Grade Assay Compared With Ki67 to Determine Risk of Distant Breast Cancer Recurrence.
    Ignatiadis M; Azim HA; Desmedt C; Veys I; Larsimont D; Salgado R; Lyng MB; Viale G; Leyland-Jones B; Giobbie-Hurder A; Kammler R; Dell'Orto P; Rothé F; Laïos I; Ditzel HJ; Regan MM; Piccart M; Michiels S; Sotiriou C
    JAMA Oncol; 2016 Feb; 2(2):217-24. PubMed ID: 26633571
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Biologic markers determine both the risk and the timing of recurrence in breast cancer.
    Esserman LJ; Moore DH; Tsing PJ; Chu PW; Yau C; Ozanne E; Chung RE; Tandon VJ; Park JW; Baehner FL; Kreps S; Tutt AN; Gillett CE; Benz CC
    Breast Cancer Res Treat; 2011 Sep; 129(2):607-16. PubMed ID: 21597921
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Long-Term Outcomes of Immunohistochemically Defined Subtypes of Breast Cancer Less Than or Equal to 2 cm After Breast-Conserving Surgery.
    Pata G; Guaineri A; Bianchi A; Amoroso V; Pasinetti N; Pasini M
    J Surg Res; 2019 Apr; 236():288-299. PubMed ID: 30694768
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Androgen receptor expression in male breast cancer predicts inferior outcome and poor response to tamoxifen treatment.
    Wenhui Z; Shuo L; Dabei T; Ying P; Zhipeng W; Lei Z; Xiaohui H; Jingshu G; Hongtao S; Qingyuan Z
    Eur J Endocrinol; 2014 Oct; 171(4):527-33. PubMed ID: 25069458
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expression of Abl interactor 1 and its prognostic significance in breast cancer: a tissue-array-based investigation.
    Wang C; Tran-Thanh D; Moreno JC; Cawthorn TR; Jacks LM; Wang DY; McCready DR; Done SJ
    Breast Cancer Res Treat; 2011 Sep; 129(2):373-86. PubMed ID: 21046228
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Tissue microarray analysis of connexin expression and its prognostic significance in human breast cancer.
    Conklin C; Huntsman D; Yorida E; Makretsov N; Turbin D; Bechberger JF; Sin WC; Naus CC
    Cancer Lett; 2007 Oct; 255(2):284-94. PubMed ID: 17583422
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Distinguishing luminal breast cancer subtypes by Ki67, progesterone receptor or TP53 status provides prognostic information.
    Feeley LP; Mulligan AM; Pinnaduwage D; Bull SB; Andrulis IL
    Mod Pathol; 2014 Apr; 27(4):554-61. PubMed ID: 24051696
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Gli1 is a potential cancer stem cell marker and predicts poor prognosis in ductal breast carcinoma.
    Ni W; Yang Z; Qi W; Cui C; Cui Y; Xuan Y
    Hum Pathol; 2017 Nov; 69():38-45. PubMed ID: 28965964
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Activation of c-jun N-terminal kinase is associated with cell proliferation and shorter relapse-free period in superficial spreading malignant melanoma.
    Jørgensen K; Davidson B; Flørenes VA
    Mod Pathol; 2006 Nov; 19(11):1446-55. PubMed ID: 16951673
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.